Navigation Links
Atrium and Kaneka Launch Xpress-Way™ RX Extraction Catheter in the U.S.
Date:1/13/2011

HUDSON, N.H., Jan. 13, 2011 /PRNewswire/ -- Atrium Medical Corporation and Kaneka Corporation are proud to announce the introduction of the Xpress-Way™ RX Extraction Catheter. Xpress-Way RX has recently received FDA 510K clearance and is indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature. The Xpress-Way RX manual extraction catheter is manufactured by Kaneka Corporation (Osaka, Japan) and Atrium Medical Corporation (Hudson, NH) is the exclusive distributor of the Xpress-Way RX in the U.S.

Thrombus aspiration uses the suction force generated from a syringe to pull soft fresh thrombus from a vessel. Thrombus can form throughout the body, but manual thrombus aspiration is commonly used in patients that have heart attacks. The main cause of heart attacks is due to a plaque rupture in one of the major coronary arteries, which causes a blood clot to form reducing blood flow and depriving the heart muscle downstream of oxygen rich blood. Manual thrombus aspiration is one tool used by interventional cardiologists to remove the blood clot and restore critical blood flow to the heart muscle.

About Xpress-Way™ RX

The Xpress-Way™ RX Extraction Catheter is an ultra low profile manual aspiration system designed for the removal of fresh, soft emboli, and thrombi in both coronary and peripheral vessels. Xpress-Way RX incorporates an innovative removable stylet and has been designed with enhanced pushability, anti-kinking, trackability, and crossability which allows for unmatched deliverability and market leading performance. Outside the United States, the Xpress-Way RX is marketed as the Thrombuster II (Kaneka Corporation, Osaka, Japan).  

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of coronary and vascular disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and hernia repair. Maintaining a commitment to the latest ISO13485 Quality Standards, late breaking advancements in manufacturing and automation, cell biology and biomaterial research, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for life sustaining patient care. For more information please call Atrium's Marketing Communications Dept. at 1-800-370-7899 or visit Atrium's website at www.atriummed.com.

About Kaneka Corporation

Kaneka is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers. The medical device activity is currently one of the strategically important domains for Kaneka. With polymer and life science technologies, unique extracorporeal blood purification systems have been developed and become available in Japan, EU, and U.S. for patients with serious disease. In the interventional cardiology and neurology field, the company has developed high performance devices such as Thrombus Aspiration Catheter, Balloon Catheters, Embolization Coils, etc.

Kaneka Corporation is headquartered in Osaka-Japan, with subsidiaries in Belgium, the United States, Singapore, Malaysia, China, Australia and Vietnam. Net sales in the last financial year were 412 billion Yen, corresponding to about 4.4 billion U.S. dollars. Kaneka employs more than 7,700 people worldwide. Information is available at http://www.kaneka.co.jp/kaneka-e/index.html


'/>"/>
SOURCE Atrium Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
2. Atrium Responds to Bard Suit
3. Atrium Recognized by Business NH Magazine
4. Atrium Recognized by New Hampshire Bio/Medical Council
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):